SUNANDANA CHANDRA, M.D.
Medical Oncology Physician · CHICAGO, IL
Individual Active NPI 1265696348
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 435 | 74,604 | $8,714,096 | $2,476,274 | $1,974,798 |
| 2023 | 501 | 87,290 | $10,719,165 | $2,775,363 | $2,207,917 |
| 2022 | 522 | 114,734 | $13,792,413 | $3,937,712 | $3,139,796 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | 8,520 | $31 | $25 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,660 | $49 | $39 |
| J9380 | Injection, teclistamab-cqyv, 0.5 mg | 6,426 | $31 | $24 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 5,741 | $0 | $0 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 4,800 | $44 | $35 |
| J9271 | Injection, pembrolizumab, 1 mg | 4,400 | $48 | $38 |
| J1453 | Injection, fosaprepitant, 1 mg | 3,150 | $0 | $0 |
| J9047 | Injection, carfilzomib, 1 mg | 2,620 | $47 | $38 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 960 | $20 | $16 |
| J9041 | Injection, bortezomib, 0.1 mg | 910 | $2 | $1 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 540 | $0 | $0 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 370 | $1 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 262115 | NY |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Illinois
- NPI 1013273614
- NPI 1891761532
- NPI 1134448665
- NPI 1134205081
- NPI 1619234218
- NPI 1922327535
- NPI 1992948152
- NPI 1295701738
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.